News from alterity therapeutics limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 09, 2021, 08:53 ET Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox...

Jan 07, 2021, 08:00 ET Dr David Stamler Appointed CEO

The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr David Stamler...

Dec 21, 2020, 16:42 ET Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the...

Nov 16, 2020, 08:42 ET Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent...

Oct 26, 2020, 22:03 ET Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System ...

Aug 03, 2020, 21:33 ET New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for ...

Jul 30, 2020, 18:49 ET Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update...

May 20, 2020, 20:58 ET Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of...

Apr 30, 2020, 04:35 ET Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update...

Feb 07, 2020, 08:00 ET Alterity Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received notification from the Listing Qualifications Department of NASDAQ advising the...